Open AccessThe Role of β-1.3/1.6-D-Glucan From Ganoderma lucidum Mycelium Extract in Ulcerative Colitis
Author(s) -
Marcellus Simadibrata,
Aditya Rachman,
Saskia Aziza Nursyirwan,
Murdani Abdullah,
Rabbinu Rangga Pribadi,
Raja Mangatur Haloho,
Anthony Eka Wijaya,
Daniel Martin Simadibrata,
Kaka Renaldi
Publication year - 2022
Publication title -
the indonesian journal of gastroenterology, hepatology, and digestive endoscopy/the indonesian journal of gastroenterology hepatology and digestive endoscopy
Language(s) - English
Resource type - Journals
eISSN - 2302-8181
pISSN - 1411-4801
DOI - 10.24871/2232021234-239
Subject(s) - ulcerative colitis , ganoderma lucidum , mycelium , glucan , colitis , polysaccharide , inflammatory bowel disease , medicine , inflammation , pharmacology , immunology , chemistry , traditional medicine , disease , biology , biochemistry , botany
Ulcerative colitis (UC) is an idiopathic inflammatory disease that affects the colon. Current pharmacological modalities to treat UC have various side effects; therefore, there is a demand to develop a new alternative medicine that can reduce side effects and increase drug efficacy. One candidate for alternative therapy is Polysaccharide Peptide which is extracted from Ganoderma lucidum mycelium. This Polysaccaharide has an active compound of Β-1,3/1,6-D-Glucan which has strong immunomodulatory and anti-inflammatory properties. Various studies have reported that Ganoderma lucidum polysaccharides can reduce inflammatory markers such as TNF-α, IFN-γ, and IL-17A, which is produced by colonic mucosal inflammation. In addition, β-1,3/1,6-D-Glucan has shown improvements in inflammatory parameters and intestinal immunological barrier function animal studies with artificial colitis and requires further research in humans before clinical applications.